Carol Levy, MD
Endocrinology, Diabetes & Metabolism · New York, NYNPI 1710074893
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (38.9%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Dexcom, Inc. at 53.9% of the total. Reporting peaked in 2023 at $22,780 and has fallen 63.5% since, to $8,308 in 2025. Among endocrinology, diabetes & metabolism clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 58 payments — averaging $1129.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$35K
- Sanofi-aventis U.S. LLC$13K
- Tandem Diabetes Care, Inc.$6K
- Eli Lilly$5K
- Mannkind Corporation$4K
- Insulet Corporation$2K
- plus $313 from 4 others
Across 312 payments — averaging $6745.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dexcom, Inc.$859K
- Insulet Corporation$465K
- Tandem Diabetes Care, Inc.$358K
- Sequel Med Tech, LLC$237K
- Mannkind Corporation$142K
- Abbott$43K
- plus $597 from 1 others
What the payments were for
- Consulting fees$25,52039%
- Speaking & faculty fees$12,35719%
- Travel & lodging$24,22837%
- Food & beverage$3,4255%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 25 | $35,296 |
| Sanofi-aventis U.S. LLC | 7 | $12,690 |
| Tandem Diabetes Care, Inc. | 11 | $5,932 |
| Eli Lilly | 1 | $5,250 |
| Mannkind Corporation | 4 | $4,116 |
| Insulet Corporation | 5 | $1,933 |
| Medtronic | 2 | $175 |
| Salvin Dental Specialties, Inc. | 1 | $62 |
| Boehringer Ingelheim | 1 | $46 |
| Novo Nordisk | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G7 GSS (161)$22,641
- SOTAGLIFLOZIN$12,586
- DEXCOM G6 TRANSMITTER$6,473
- t:slim X2 Insulin Pump with Control-IQ$5,540
- DEXCOM G6 CGM SYSTEM$5,500
- AFREZZA$4,046
- Omnipod$1,887
- MINIMED 780G$167
- t-slim insulin pump$150
- DEXCOM CGM$103
How this compares
$65,530 in reported general payments places this provider in the 90th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 39 | $44,402 |
| OzempicSemaglutide | 32 | $41,129 |
| MounjaroTirzepatide | 18 | $23,181 |
| RybelsusSemaglutide | 15 | $21,139 |
| JanuviaSitagliptin Phosphate | 13 | $12,654 |
| Victoza 3-PakLiraglutide | 13 | $12,599 |
| NovologInsulin Aspart | 26 | $6,569 |
| HumalogInsulin Lispro | 19 | $4,877 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 21 | $1,500 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 15 | $1,328 |
| SynthroidLevothyroxine Sodium | 13 | $1,307 |
| Metformin Hcl ErMetformin Hcl | 35 | $413 |
| Losartan Potassium | 20 | $369 |
| Levothyroxine Sodium | 34 | $285 |
| Metformin Hcl | 21 | $210 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $30 | $68,83773 claims |
| Boehringer IngelheimJardiance | $46 | $44,40239 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in New York
- John BilezikianNew York$809K
- Anastasios ManessisNew York$656K
- Jason BakerNew York$427K
- Brian LevyNew York$417K
- Stuart WeissNew York$275K
- Priya JaisinghaniNew York$239K
- Henry GinsbergNew York$161K
- Recaredo BerbanoNew York$146K
- Beverly TchangNew York$120K
- Shira EytanNew York$96K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.